Introduction {#S0001}
============

Acute myeloid leukemia (AML), a molecularly and clinically heterogeneous disease, is characterized by differentiation arrest and uncontrolled proliferation of myeloid progenitor cells, which ultimately interferes with the production of normal blood cells.[@CIT0001] Although recent treatment advances in hematopoietic stem cell transplantation and intensive chemotherapy, the clinical outcome for AML remained unsatisfied.[@CIT0002] Since treatment with all-trans retinoic acid (ATRA) has dramatically improved the outcome of acute promyelocytic leukemia (APL) by binding to retinoic acid receptor α, the development of molecular risk-adapted treatment strategies and targeted therapies may improve the clinical outcome of AML.[@CIT0003] Therefore, the identifying biological markers correlated with prognosis, and recurrence is required for better management of AML patients and may provide potential targets for AML therapy. B-cell leukemia/lymphoma-2 (*BCL-2*) protein family consists of a pro-survival group and two pro-apoptotic subgroups. The pro-survival group comprise *BCL-2*, myeloid cell leukemia-1 (*MCL-1), BCL-2* and *BCL-2*-like protein 1 isoform 1 (*BCL-XL*), which play important roles in regulating cell apoptosis, proliferation, differentiation and tumorigenesis.[@CIT0004]--[@CIT0008] Among them, *MCL-1*, isolated from a human myeloblastic leukemia cell line, can affect the development of tumor through the expression of its mRNA and protein in many cancers.[@CIT0009]--[@CIT0011] Allen et al indicated that overexpression of *MCL-1* was related to poor overall survival (OS) in non-small cell lung cancer when *MYC* was up-regulated simultaneously.[@CIT0006] In breast cancer, *MCL-1* high-expressed was associated with later tumor stage and worse survival.[@CIT0012] Glaser et al also found that knockdown of *MCL-1*, but not loss or pharmacological blockade of *Bcl-xL*, *Bcl-2* or *Bcl-w*, caused the death of transformed AML and could cure disease in AML-afflicted mice.[@CIT0013] Recently, *MCL-1* protein inhibitor S63845 was reported to kill *MCL-1*-dependent cancer cells and has potential value in clinical application.[@CIT0014] Herein, we aimed to investigate the *MCL-1* expression pattern as well as its clinical implication in Chinese *de novo* patients with AML and may provide theoretical basis for AML patients using *MCL-1* protein inhibitor in clinics.

Materials and methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

This study was approved by the Institutional Ethics Committee of the Affiliated People's Hospital of Jiangsu University. Bone marrow (BM) aspirate specimens of 151 patients newly diagnosed AML, 26 healthy donors, 52 AML patients achieving complete remission and 23 relapsed AML patients were collected after written informed consent was signed. The diagnosis and classification of the patients were based on the 2008 WHO criteria.[@CIT0015] All patients were treated at the Affiliated People's Hospital of Jiangsu University from October 2005 to December 2016. Treatment protocol was described as reported previously.[@CIT0016] The characteristics of all patients are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Comparison of clinical manifestations and laboratory features between AML patients with low and high *MCL1* expressionPatient's parametersHigh (*n*=75)Low (*n*=76)*P*-valueSex, male/female44/3147/290.741Median age, years (range)60 (10--93)52 (15--85)0.029Median WBC, ×10^9^/L (range)19.5 (0.3--197.7)16.6 (0.9--528)0.248Median hemoglobin, g/L (range)77 (34--144)77 (34--123)0.849Median platelets, ×10^9^/L (range)40 (8--399)34 (3--415)0.355BM blasts, % (range)\*50 (1--94.5)43 (5.5--97.5)0.348Karyotype classification0.465 Favorable18 (24%)25 (33%) Intermediate45 (60%)41 (54%) Poor10 (13%)8 (10%) No data2(3%)2 (3%)Karyotype0.042 normal31 (41%)34 (45%) t(8;21)8 (11%)6 (8%) t(16;16)1 (1%)0 (0%) t(15;17)8 (11%)19 (25%) +82 (3%)3 (4%) −5/5q-3 (4%)0 (0%) −7/7q-0 (0%)1 (1%) t(9;22)1 (1%)1 (1%) others12 (16%)3 (4%) complex7 (9%)7 (9%) No data2 (3%)2 (3%)Gene mutation *CEBPA* (±)4/608/530.234 *NPM1* (±)10/542/590.030 *FLT3*-ITD (±)8/567/541.000 *c-KIT* (±)2/624/570.432CR, all AML (±)\*\*49/2430/380.007CR, non-APL AML (±)48/1727/240.031CR, CN-AML (±)24/712/180.004[^2][^3]

BMMNCs separation, RNA isolation and reverse transcription {#S0002-S2002}
----------------------------------------------------------

BM mononuclear cells (BMMNCs) were separated by Lymphocyte Separation Medium (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed as reported previously.[@CIT0017],[@CIT0018]

Real-time quantitative PCR {#S0002-S2003}
--------------------------

Real-time quantitative PCR (RQ-PCR) was used to detect *MCL-1* expression level on a 7,300 Thermo cycler (Applied Biosystems, CA, USA). AceQ qPCR SYBR Green Master Mix Kit (Vazyme Biotech Co., Piscataway, NJ, USA) and ROX Reference Dye 1 (Invitrogen, Carlsbad, CA, USA) were applied to RQ-PCR reactions. The primers (forward 5ʹ-GATGATCCATGTTTTCAGCGAC-3ʹ and reverse 5ʹ-CTGGGATGGGTTTGTGGAG-3ʹ) were used for *MCL-1* transcript detection. The housekeeping gene *ABL* detected by 2× SYBR Green PCR Mix (Multisciences, Hangzhou, China) was used to calculate the abundance of *MCL-1* transcript. The primers of *ABL* expression were 5ʹ-TCCTCCAGCTGTTATCTGGAAGA-3ʹ (forward) and 5ʹ-TCCAACGAGCGGCTTCAC-3ʹ (reverse). The RQ-PCR was carried out at 95°C for 5 mins, followed by 40 cycles at 95°C for 10 s, 60°C (*MCL-1*) or 60°C (*ABL*) for 30 s, 72°C for 32 s and 80°C for 32 s to collect fluorescence, finally followed by 95°C for 15 s, 60°C for 60 s, 95°C for 15 s and 60°C for 15 s. Relative *MCL-1* expression levels were calculated by 2^−△△CT^ method.

Gene mutation detection {#S0002-S2004}
-----------------------

*NPM1* and *C-KIT* mutations were detected by high-resolution melting analysis using the LightScanner platform (Idaho Technology Inc., Salt Lake City, Utah, USA).[@CIT0020] *FLT3-ITD* and *CEBPA* mutations were detected by direct DNA sequencing (BGI Tech Solutions Co., Shanghai, China).[@CIT0019],[@CIT0020] Both positive (leukemic cell lines samples, cultured in RPMI-1640 medium containing 10% fetal calf serum \[ExCell Bio, Shanghai, China\]) and negative controls (ddH2O) were included in each assay.

Gene expression profiling data {#S0002-S2005}
------------------------------

Gene expression profiling (GEP) data (accession number GSE12417, <http://www.ncbi.nlm.nih.gov/geo/>) was used to validate the prognostic value of *MCL-1* expression in two independent cohorts of 162 and 78 cytogenetically normal AML (CN-AML) patients by the online web tool Genomicscape (<http://genomicscape.com/microarray/survival.php>).[@CIT0021]

Statistical analysis {#S0002-S2006}
--------------------

Statistical analyses were performed using the SPSS 20.0 software package. Mann--Whitney's *U* test was carried to compare the difference of continuous variables between two groups. Pearson Chi-square analysis or Fisher exact test was employed to compare the difference of categorical variables. Kaplan--Meier analysis and Cox regression analyses were performed to analyze the impact of *MCL-1* expression on OS and leukemia-free survival (LFS) in AML. Receiver operating characteristic curve (ROC) and area under the ROC curve (AUC) were conducted to assess the value of *MCL-1* expression in discriminating AML patients from normal controls. For all analyses, a two-tailed *P*-value of 0.05 or less was determined as statistically significant.

Results {#S0003}
=======

MCL-1 expression in controls and AML patients {#S0003-S2001}
---------------------------------------------

As is shown in [Figure 1](#F0001){ref-type="fig"}, *MCL-1* transcript level in 151 AML patients (range 0.0000--311.0063, median 6.6821) was significantly higher as compared with 26 controls (range 0.0002--22.4120, median 3.7865), which indicated that *MCL-1* expression was up-regulated in AML (*P*=0.042). In addition, increased *MCL-1* expression was also presented in both 123 non-APL (range 0.0000--311.0063, median 10.6716) and 65 CN-AML (range 0.0023--108.2933, median 5.1723) patients (*P*=0.005 and 0.044, respectively, [Figure 1](#F0001){ref-type="fig"}).Figure 1*MCL-1* expression in AML patients. *MCL-1* expression in 151 newly diagnosis (range 0.0000--311.0063, median 6.6821), 123 non-APL (range 0.0000--311.0063, median 10.6716) and 65 CN-AML (range 0.0023--108.2933, median 5.1723) patients were significantly upregulated in 26 controls (range 0.0002--22.4120, median 3.7865).**Abbreviations:**AML, acute myeloid leukemia; CN-AML, cytogenetically normal AML.

Discriminative capacity of MCL-1 expression {#S0003-S2002}
-------------------------------------------

ROC was used to evaluate the discriminative capacity of *MCL-1* expression. It revealed that *MCL-1* expression could act as a potential biomarker for distinguishing whole-cohort AML (AUC=0.625, 95% CI: 0.526--0.723, *P*=0.043, [Figure 2A](#F0002){ref-type="fig"}), non-APL AML (AUC=0.676, 95% CI: 0.577--0.774, *P*=0.005, [Figure 2B](#F0002){ref-type="fig"}) and CN-AML (AUC=0.636, 95% CI: 0.515--0.756, *P*=0.044, [Figure 2C](#F0002){ref-type="fig"}) from normal controls.Figure 2ROC curve analysis using *MCL-1* expression for discriminating AML patients from controls. (A) all AML; (B) non-APL; (C) CN-AML.**Abbreviations:** AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ROC, receiver operating characteristic curve; CN-AML, cytogenetically normal AML.

Clinical and laboratory characteristics of AML patients {#S0003-S2003}
-------------------------------------------------------

In order to investigate the clinical implication of *MCL-1* expression in AML, we further divided the patients into two groups (*MCL-1*^high^ and *MCL-1*^low^) based on the median level of 6.6821. The comparison of clinical characteristics of two groups is presented in [Table 1](#T0001){ref-type="table"}. *MCL-1*^high^ patients showed older age as compared with *MCL-1*^low^ patients (*P*=0.029). Moreover, there was a significant difference in the distribution of karyotypes between two groups (*P*=0.042). However, no significant differences were found between the two groups in the sex, white blood cell (WBC), hemoglobin, platelets, percentage of BM blasts and karyotype classification (*P*\>0.05). *MCL-1*^high^ patients had a significantly higher frequency of *NPM1* mutation than *MCL-1*^low^ patients ([Table 1](#T0001){ref-type="table"}). No significant differences were observed between *MCL-1*^high^ and *MCL-1*^low^ groups among other gene mutations.

Effect of MCL-1 expression on chemotherapy response in AML {#S0003-S2004}
----------------------------------------------------------

The follow-up data is available in 141 patients after induction chemotherapy. *MCL-1*^high^ patients presented significantly lower CR rate than *MCL-1*^low^ patients (33% vs 57%, *P*=0.007, [Table 1](#T0001){ref-type="table"}). In addition, we further showed *MCL-1* transcript level between the patients with and without CR (*P*=0.002, [Figure 3](#F0003){ref-type="fig"}). Apart from APL patients, *MCL-1*^high^ cases also had markedly lower CR rate than *MCL-1*^low^ cases (26% vs 47%, *P*=0.031, [Table 1](#T0001){ref-type="table"}). There was also a significant difference in CR rate between the two groups in CN-AML (23% vs 60%, *P*=0.004, [Table 1](#T0001){ref-type="table"}).Figure 3The comparison of *MCL-1* expression among AML patients with and without CR. *MCL-1* expression among AML patients (*n*=62, range 0.0000--105.5293, median 3.9643) who could achieve CR was significantly lower than those who could not achieve CR (*n*=79, range 0.0000--311.0063, median 15.5237) after induction therapy.**Abbreviations:** AML, acute myeloid leukemia; CR, complete remission.

Correlation between MCL-1 expression and clinical outcome {#S0003-S2005}
---------------------------------------------------------

To investigate the prognostic significance of *MCL-1* expression in AML, 141 AML patients with follow-up data (median 8 months, range 1--115 months) were included in survival analysis. Due to independent disease entity, APL was excluded from the analysis. Kaplan--Meier analyses revealed that there was a significant difference in OS time between *MCL-1*^high^ and *MCL-1*^low^ groups in non-APL patients (median 4 vs 9 months, respectively, *P*=0.008, [Figure 4A](#F0004){ref-type="fig"}). *MCL-1*^high^ patients also had a shorter OS time than *MCL-1*^low^ patients in CN-AML patients (median 3 vs 16.5 months, respectively, *P*=0.004, [Figure 4B](#F0004){ref-type="fig"}). In addition, multivariate analysis, including variables (age (\>60/≤60y), WBC (≥30/\<30\*10^9^/L), *MCL-1* expression (high/low) and gene mutations) with *P*\<0.200 in univariate analysis, demonstrated that increased expression of *MCL-1* was an independent adverse prognostic factor for OS among both non-APL and CN-AML patients ([Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}). However, there was no significant difference in LFS between two groups both in non-APL (*P*=0.157) and CN-AML patients (*P*=0.228).Table 2Univariate and multivariate analyses of prognostic factors for overall survival in non-APL patientsPrognostic factorsUnivariate analysisMultivariate analysisHazard ratio (95% CI)*P*-valueHazard ratio (95% CI)*P*-valueAge2.433 (1.599--3.702)\<0.0012.088 (1.359--3.207)0.001WBC2.118 (1.405--3.193)\<0.0011.000 (0.997--1.002)0.804Karyotype1.744 (1.404--2.165)\<0.0011.751 (1.266--2.421)0.001*MCL-1* expression1.710 (1.125--2.600)0.0121.777 (1.164--2.714)0.008*FLT3*-ITD mutation1.403 (0.698--2.822)0.342\--*NPM1* mutation1.484 (0.738--2.982)0.268\--*CEBPA* mutation0.818 (0.375--1.783)0.613\--*c-KIT* mutation0.613 (0.150--2.503)0.496\--[^4] Table 3Univariate and multivariate analyses of prognostic factors for overall survival in CN-AML patientsPrognostic factorsUnivariate analysisMultivariate analysisHazard ratio (95% CI)*P*-valueHazard ratio (95% CI)*P*-valueage2.437 (1.336--4.447)0.0042.126 (1.155--3.914)0.015WBC2.348 (1.312--4.202)0.0041.755 (0.958--3.215)0.069*MCL1* expression2.235 (1.238--4.035)0.0081.876 (1.013--3.473)0.045*FLT3*-ITD mutation0.941 (0.361--2,452)0.901\--*NPM1* mutation1.311 (0.545--3.149)0.545\--*CEBPA* mutation1.055 (0.409--2.718)0.912\--*c-KIT* mutation0.631 (0.086--4.643)0.651\--[^5][^6] Figure 4The impact of *MCL-1* expression on prognosis of AML patietns. Overall survival between *MCL-1*^high^ and *MCL-1*^low^ group. (A) non-APL patients; (B) CN-AML patients.**Abbreviations:** AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CN-AML, cytogenetically normal AML.

To further validate the prognostic impact of *MCL-1* expression in CN-AML patients, we focused on the GEP data (accession number GSE12417) using the online web tool Genomicscape.[@CIT0021] *MCL-1*^high^ cases showed shorter OS time than *MCL-1*^low^ cases in two independent cohorts of CN-AML patients (*P*=0.022 and *P*=0.007, respectively, [Figure 5](#F0005){ref-type="fig"}).Figure 5Prognostic value of *MCL-1* expression validated by public database. Gene expression profiling (GEP) data (accession number GSE12417, <http://www.ncbi.nlm.nih.gov/geo/>) was used to validate the prognostic value of *MCL-1* expression in two independent cohorts of 162 and 78 cytogenetically normal AML (CN-AML) patients by the online web tool Genomicscape (<http://genomicscape.com/microarray/survival.php>).

Surveillance of MCL-1 expression in follow-up AML patients {#S0003-S2006}
----------------------------------------------------------

To investigate whether the expression of *MCL-1* could monitor disease recurrence in AML, we assessed *MCL-1* expression in 52 AML patients in CR and 23 cases in relapse. The median *MCL-1* levels in patients at CR and relapse were 3.194 (range 0.000 to 76.368) and 12.076 (range 0.216--151.220), respectively. Obviously, *MCL-1* expression was significantly decreased in CR time and was significantly increased in relapsed time compare with initial diagnosis time (*P*=0.020 and *P*=0.004, respectively, [Figure 6](#F0006){ref-type="fig"}). In addition, the dynamic change of *MCL-1* expression in the five paired AML patients of different stages ([Figure 7](#F0007){ref-type="fig"}).Figure 6*MCL-1* expression in different clinical stages of AML. *MCL-1* expression in 151 newly diagnosis, 52 AML patients achieving CR (range 0.000--76.368, median 3.194), and 23 relapsed (range 0.216--151.220, median 12.076) AML patients.**Abbreviations:** AML, acute myeloid leukemia; CR, complete remission.Figure 7Dynamic change of *MCL-1* expression in the five paired AML patients of different clinical stages. White column: newly diagnosed AML patients; Gray column: AML patients who achieved CR; Black column: relapsed AML patients.**Abbreviations: **AML, acute myeloid leukemia; CR, complete remission.

Discussion {#S0004}
==========

Accumulating studies stated that *MCL-1* expression was associated with the progression and outcome of various human malignant tumors.[@CIT0004]--[@CIT0006] In multiple myeloma, *MCL-1* high-expression was reported to be associated with relapse and shorter event-free survival.[@CIT0011] Mylin et al demonstrated that *MCL-1* was up-regulated in multiple myeloma compared with monoclonal gammopathy of undetermined significance, but had no impact on OS and event-free survival.[@CIT0022] Moreover, the activated vascular endothelial growth factor induced the overexpression of *MCL-1* and predicted a poor outcome and aggressive disease progression in non-Hodgkin's lymphoma.[@CIT0023] More interestingly, Kempkensteffen et al elucidated that the antiapoptotic full-length splicing variant of *MCL-1*, down-regulation in clear-cell renal cancer, was related with poor tumor differentiation and predicted a higher risk for relapse; they also revealed that low *MCL-1L* was associated with short recurrence-free and disease-specific survival.[@CIT0024] Glaser et al used RNAi for knockdown of *MCL-1* to determine that *MCL-1* was essential for development and sustained growth of this hematological malignancy and it could be targeted for therapeutic benefit.[@CIT0013] In this study, we observed that up-regulation of *MCL-1* expression was a frequent event in Chinese *de novo* AML patients. Survival analyses revealed that high *MCL-1* expression was associated with shorter OS both in non-APL and in CN-AML patients. Notably, our data showed that high-expression of *MCL-1* had lower CR rate. Meanwhile, expression of *MCL-1* in CR and relapsed patients illustrated that *MCL-1* were significantly decreased from the initial diagnosis to CR and increased after relapsed. These results together indicated that *MCL-1* expression was a valuable predictor in assessing treatment outcome as well as status,and might serve as a criterion for the therapeutic evaluation in AML.

It has been well demonstrated that *BCL-2* family proteins act as positive or negative regulators on cellular apoptosis and druggable targets.[@CIT0004]--[@CIT0011],[@CIT0025] Kaufmann et al found that cells overexpressing *MCL-1* were resistant to a variety of chemotherapeutic agents and raised the possibility that some chemotherapeutic regimens might select for leukemia cells with elevated levels of this particular apoptosis inhibitor.[@CIT0026] Recently, ABT-199, a highly potent and selective inhibitor of *BCL-2*, has been granted breakthrough designation by FDA for relapsed or refractory chronic lymphocytic leukemia with 17p deletion.[@CIT0027] Moreover, Pan et al found that ABT-199 also potently killed a diverse array of AML cell lines by establishing an aggressive mouse xenograft model of MOLM-13.[@CIT0027] Notably, some scholars stated that *MCL-1* induced the resistance to ABT-737 (the first molecule studied extensively preclinically) and its analogs ABT-263 (the first of this series to enter the clinic) and ABT-199,[@CIT0028]--[@CIT0030] while *MCL-1* suppression could restore sensitivity to these compounds in leukemia cells,[@CIT0031],[@CIT0032] suggesting that drug resistance was attributed to high level of *MCL-1*. Kotschy et al found that the selective *MCL-1* inhibitor S63845 killed *MCL-1*-dependent cancer cells by activating the *BAX/BAK-*dependent mitochondrial apoptotic pathway in diverse cancer models.[@CIT0014] Doi et al showed that maritoclax, a novel kind of *BCL-2* family inhibitors, induced the selective degradation of *MCL-1* through the proteasome to kill AML cells that express elevated levels of *MCL-1*.[@CIT0033] Recently, Wang et al revealed that inhibition of CDK9, a key component of the positive transcriptional regulator complex pTEFb which activates transcription via phosphorylation of RNA polymerase II, blocked transcription resulting in the repression of short-lived proteins such as *MCL-1*.[@CIT0034] Dey J et al found that voruciclib, a novel CDK9 inhibitor which addressed a well-characterized key-mediator of resistance to venetoclax by repressing *MCL-1*, and the *BCL-2* specific inhibitor, venetoclax, with promise for treating high-risk subtype of diffuse large B-cell lymphoma by establishing specific models.[@CIT0035] Previous researches proved that higher levels of *MCL-1* have been reported to result in the failure to achieve CR after fludarabine and chlorambucil treatment,[@CIT0036],[@CIT0037] while higher *MCL-1*/*BAX* ratio was related to poor response to rituximab in some patients.[@CIT0038] Taken together, these results suggested that *MCL-1* combined with other targets have great potential in AML targeted therapies.

In addition, our study further observed that *MCL-1* overexpression was associated with *NPM1* mutation, which was a favorable prognostic indicator in AML and frequently occurred in patients with normal karyotype.[@CIT0039] In some studies, AML patients with *NPM1* mutation appeared to benefit from ATRA as an adjunct to conventional chemotherapy.[@CIT0040],[@CIT0041] Moreover, it was reported that AML cells carrying *NPM1* mutation were more sensitive to ATO, because of the expression of *NPM1* mutant protein and its acquired C-terminus cysteine 288.[@CIT0042] Martelli et al also showed that ATO/ATRA induced proteasome-dependent degradation of *NPM1* leukemic protein leading to cell growth inhibition and apoptosis in *NPM1*-mutated AML.[@CIT0043] Although a large number of findings suggest that the *NPM1* mutation has a favorable effect on the outcome for AML.[@CIT0044]--[@CIT0047] Falini et al found that *NPM1* exon 12 mutations which caused cytoplasmic dislocation of *NPM* were related to the malignant clone and leukemogenesis.[@CIT0048] Moreover, a study conducted by Konoplev et al suggested that *NPM1* mutations did not impact OS and event-free survival (EFS) in AML patients.[@CIT0049] However, Verhaak et al demonstrated that patients with intermediate cytogenetic risk AML with *NPM1* mutations had a significantly better OS and EFS than those without *NPM1* mutations.[@CIT0044] Further studies are needed to confirm and reveal the underlying association between *MCL-1* expression and *NPM1* mutation.

Collectively, these results demonstrated that *MCL-1* is overexpressed and confers a poor prognosis in Chinese *de novo* AML patients and could be also used as a potential therapeutic target in the treatment of newly diagnosed and relapsed AML.
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Abbreviation list {#S0005}
=================

AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; AUC, area under the ROC curve; *BCL-2*, B-cell leukemia/lymphoma-2; *BCL-XL, BCL-2* and *BCL-2*-like protein 1 isoform 1; BM, Bone marrow; BMMNCs, BM mononuclear cells; CN-AML, cytogenetically normal AML; CR, complete remission; GEP, melting analysis; LFS, leukemia-free survival; *MCL-1*, myeloid cell leukemia-1; OS, overall survival; PLT, platelets; RARα, retinoic acid receptor α; ROC, Receiver operating characteristic curve; RQ-PCR, Real-time quantitative PCR; WBC, white blood cell; WHO, World Health Organization.
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[^3]: **Abbreviations:** AML, acute myeloid leukemia; WBC, white blood cells; BM, bone marrow; CR, complete remission; CN-AML,cytogenetically normal AML.

[^4]: **Notes:** Multivariate analyses, including variables \[age (\>60/≤60 y), WBC (≥30/\<30\*10^9^/L), *MCL-1* expression (high/low), and gene mutations\] with *P*\<0.200 in univariate analysis.

    **Abbreviations:** APL, acute promyelocytic leukemia; WBC, white blood cells.

[^5]: **Notes:** Multivariate analyses, including variables \[age (\>60/≤60 y), WBC (≥30/\<30\*10^9^/L), *MCL-1* expression (high/low), and gene mutations\] with *P*\<0.200 in univariate analysis.

[^6]: **Abbreviations:** AML, acute myeloid leukemia;  CN-AML: cytogenetically normal AML; WBC: white blood cells.
